Trial Profile
A Phase II Study of VELCADE (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 21 Sep 2009 Results published in the Journal of Clinical Oncology.
- 17 Oct 2006 Status change
- 07 Sep 2005 New trial record.